Cobra Biologics and UK CPI team on AAV vector production platform

By Gareth Macdonald

- Last updated on GMT


Related tags National biologics manufacturing Innovation Manufacturing

Cobra Biologics and the UK Centre for Process Innovation (CPI) will develop a manufacturing system for the viruses used to deliver gene therapies.

The plan is to create a scalable Adeno-Associated Virus (AAV) production platform that gene therapy developers working at the CPI’s National Biologics Manufacturing Centre (NBMC) in Darlington can use to manufacture trial supplies.

Cobra CSO Daniel Smith told us the collaboration will combine his firm’s capabilities in bioprocessing, manufacturing and QA with the CPI team’s expertise in high throughput process development and optimisation.

The collaborative project between Cobra Biologics and CPI’s National Biologics Manufacturing Centre will allow both parties to pursue goals that would be very difficult to achieve separately, bringing strong project management, cross-site working & innovation management.”

He added that: “By working together the timelines for project can be shortened, thereby allowing faster exploitation of the project outputs.”

These outputs will include the system itself and the intellectual property surrounding, ownership of which will be shared.

Smith told us: “Process and platform know how will be retained within Cobra Biologics for the manufacture of AAV products, CPI will gain knowledge of high through-put viral analytics whist validating their role as a technology innovation centre with the UK for bioprocessing innovation.”

The £1.8m ($2.5m) project is being funded to a value of £1.4m by Innovate UK via their 2015 competition for the development of regenerative medicines and cell therapies​. 

The NBMC​ is intended to allow firm to assess the manufacturability of innovative biopharmaceutical products.

Related news

Show more

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers

Follow us


View more